CompanDX | GenomeWeb

CompanDX

The collaboration draws on ResearchDx's ability to design, produce, and validate tests, and CompanDx's Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality.

Under the terms of the multi-year agreement, the partners will advance diagnostic tests, from biomarker discovery to test validation, applying CompanDx's Risk Distiller bioinformatics tool and CRL's CLIA-certified laboratory services.

The partners said they will collaborate on the development of biomarker panels and companion diagnostics for pharmaceutical, biotech, and academic clients worldwide.

The 31-gene signature, used to predict the time to cancer metastasis after initial surgery and biopsy, has been validated by CompanDX researchers in four different datasets, according to the company.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.